Gamida Cell Ltd. is an Israeli company established in 1998. The company is a pioneer in cell therapy, working to turn cells into powerful therapies. The company applies a proprietary extended platform utilizing the properties of nicotinamide to allogeneic cell sources, including cord blood-derived cells and natural killer cells, to create cell therapy candidates that may redefine the standard of care. The company's lead product candidate is omidubicel, an advanced cell therapy product candidate for allogeneic hematopoietic stem cell transplantation that, if approved, has the potential to expand treatment coverage and improve treatment outcomes for blood cancer patients. 

GMDA(Delisted)

GMDA Profile